castration-resistant

Bicalutamide (ICI-176334) 是一种具有口服活性的非甾体雄激素受体拮抗剂，可研究前列腺癌。

IPI-9119 是一种具有口服活性、选择性和不可逆的 FASN 抑制剂 (IC50 = 0.3 nM)。

Enzalutamide carboxylic acid 是 Enzalutamide 非活性代谢物。Enzalutamide 是雄激素受体 (AR) 拮抗剂。

Y06137 是一种有效的特异性 BET 抑制剂，对 BRD4(1) 溴结构域的 Kd 为 81 nM。 Y06137可用于去势抵抗性前列腺癌治疗的研究。

MC-1-F2 是一种 FOXC2 直接抑制剂，具有抗癌活性，抑制癌症干细胞 (CSC) 特性，降低去势抵抗性前列腺癌 (CRPC) 细胞系的侵袭能力。MC-1-F2 可用于研究前列腺癌。

Cabazitaxel (taxoid XRP6258) 是一种紫杉烷类的抗肿瘤剂，可用于治疗多西他赛失败后的去势抵抗性转移性前列腺癌。

Abiraterone Acetate (CB7630) 是一种具有口服活性的、不可逆的 CYP17A1选择性抑制剂，具有抗雄激素作用。它是 Abiraterone 的前药。

Bavdegalutamide (ARV-110)是一种口服蛋白质降解剂，特异性结合 AR 并介导其降解。Bavdegalutamide可以降解临床相关的突变 AR 蛋白，在高雄激素环境中保持活性并具有可接受的安全性。

Lupeol (Monogynol B) 是一个活跃的五环三萜，具有抗氧化剂、抗肿瘤和抗炎活性。它是一种雄激素受体抑制剂，可研究癌症，特别是雄激素依赖表型和去势抵抗表型的前列腺癌。

(S,R,S)-AHPC-Me hydrochloride (VHL ligand 2 hydrochloride) 是一种化学化合物，应用于合成ARV-771，一种极其强效的BET蛋白降解剂。该化合物在对去势抵抗的细胞中特异性地降解BET蛋白，其DC50值显著小于1 nM。作为VHL ligand 2 hydrochloride，(S,R,S)-AHPC-Me hydrochloride作为来源于(S,R,S)-AHPC的VHL配体，用于募集von Hippel-Lindau (VHL)蛋白。

Proxalutamide 是具有口服活性的雄激素受体的拮抗剂。它可研究前列腺癌和COVID-19。

(S,R,S)-AHPC-Me dihydrochloride, also known as VHL ligand 2 dihydrochloride, is a chemical compound utilized in the synthesis of ARV-771. ARV-771, a BET PROTAC degrader relying on von Hippel-Landau (VHL) E3 ligase, demonstrates potent degradation of BET protein in castration-resistant prostate cancer (CRPC) cells, with a DC50 of less than 1 nM. This compound serves as the VHL ligand, specifically the (S,R,S)-AHPC-based VHL ligand, that facilitates the recruitment of von Hippel-Lindau (VHL) protein.

EC1169 is a targeted tubulysin conjugate that utilizes EC1167 as its linker. This compound shows promise in the treatment of recurrent metastatic, castration-resistant prostate cancer (MCRPC)[1].

ZNU-IMB-Z15（Compound Z15）作为雄激素受体（AR）的拮抗剂和降解剂，能够有效抑制AR阳性去势抵抗性前列腺癌（CRPC）细胞系的增殖并诱导其凋亡(apoptosis)，展现出显著的体内外抗癌活性。

(+)-JJ-74-138 为新型非竞争性雄激素受体(AR)拮抗剂，具有抑制去势抵抗前列腺癌(CRPC)中恩杂鲁胺耐药的作用。

XYD049 (compound 7d) 是一种CRBN型分子胶，专门靶向GSPT1，具有DC50为19 nM的效能，用于研究由MYC驱动的去势抵抗性前列腺癌（CRPC）。XYD049 有效抑制22Rv1细胞的生长，IC50为7 nM，并在体内表现出抗肿瘤活性。通过下调22Rv1细胞中的CRPC相关癌基因，包括AR、AR-v7、PSA和c-Myc，XYD049 展现其作用机制。此化合物由分子胶的linker (black part) NH2-C5-NH-Boc、CRBN型E3连接酶配体 (blue part) Thalidomide 4-fluoride，以及靶蛋白配体 (red part) GSPT1 ligand-1 组成，其中E3连接酶配体与linker 形成偶联物E3 Ligase Ligand-linker Conjugate 158。

BKM1644 is an effective inhibition of the proliferation of metastatic, castration-resistant PCa (mCRPC) cells.

Histone H3K27Me1 (23-34) is a peptide fragment of histone H3 that corresponds to amino acid residues 24-35 of the human histone H3.1 and H3.2 sequences. Monomethylation of histone H3 at lysine 27 is associated with actively transcribed genes and positively correlates with H3K36 trimethylation. Levels of H3K27Me1 are increased in tumor tissue isolated from patients with metastatic hormone-na ve and castration-resistant prostate cancer. Histone H3K27Me1 (23-34) has been used in epitope mapping of the lupus-derived monoclonal antibody BT164.

Thailanstatin D, an analogue of Thailanstatin A, inhibits AR-V7 gene splicing by disrupting the interaction between U2AF65 and SAP155, hindering their binding to the polypyrimidine tract situated between the branch point and the 3' splice site. This compound displays potent tumor inhibitory properties in human castration-resistant prostate cancer (CRPC) xenografts, resulting in cellular apoptosis.

(S)-Orteronel ((S)-Orteronel) 是人17，20-裂解酶 (17,20-lyase, CYP17) 选择性抑制剂(IC50:38 nM)，CYP17对(S)-Orteronel 选择性比对 11-hydroxylase 及 CYP3A4 高 1000 多倍。

HG122 is a chemical compound that effectively facilitates the degradation of androgen receptor (AR) via the proteasome pathway, leading to the inhibition of castration-resistant prostate cancer.

Rucaparib hydrochloride, also known as AG014699, is a powerful and orally active compound that inhibits PARP proteins including PARP-1, PARP-2, and PARP-3 with a Ki value of 1.4 nM for PARP1. Additionally, Rucaparib hydrochloride acts as a modest inhibitor of hexose-6-phosphate dehydrogenase (H6PD). This compound shows potential in research for castration-resistant prostate cancer (CRPC) [1] [2] [3] [4].

VPC-13789 is a highly potent, selective, and orally bioavailable antiandrogen compound that shows promise for studying and developing therapeutics for castration-resistant prostate cancer (CRPC). In LNCaP cells, VPC-13789 effectively inhibits the transcriptional activity of the androgen receptor (AR) with an IC50 value of 0.19 μM [1].

Rucaparib (AG014699) acetate is a highly effective oral inhibitor of PARP proteins, specifically targeting PARP-1, PARP-2, and PARP-3, with a Ki value of 1.4 nM for PARP1. Additionally, it exhibits inhibitory action on hexose-6-phosphate dehydrogenase (H6PD) to a moderate extent. Rucaparib acetate shows promise in the field of research for castration-resistant prostate cancer (CRPC). [1] [2] [3] [4]